expectations for the provision of medicines dr michel buchmann fip vice president 48th girp annual...

Expectations for the provision of medicinesExpectations for the provision of medicines

Dr Michel BuchmannFIP Vice President

48th GIRP Annual General Meeting 18th June 2007, GENEVA

Expectations for the provision of medicines

48th GIRP Annual General Meeting, 18th June 2007, GENEVA

Dr. Michel Buchmann, FIP Vice-President

CASE:Thursday the 1st of March 2007, a nurse at a medical centre caring for the elderly

requested my advice as a consultant pharmacist about a prescribed analgesic treatment for an 83 year old woman approaching her life’s end.

Her attending physician was unavailable. The patient was highly agitated despite the use of buprenorphine 52.5 mcg/h patches

together with a reserve medication of morphine 10mg injections twice daily.

This medical regime being inadequate, I proposed an additional half patch and the use of Temgesic instead of morphine which was unavailable both in the nursing home and

in my pharmacy.

My decision having been accepted by the physician on duty, the order was given to the wholesaler at 5.30 pm and I received the medication the same evening at 10.30pm,

I was thus able to continue my responsibilities at the centre for the remainder of the night.

The patient unfortunately passed away, but peacefully on Sunday the 4th of March.




Public/political pressure will always be concerned with health costs.

Every wish to introduce innovations with care, every innovation towards quality and excellence will be done by evaluating their costs.

The promise of molecular science is for the time being overestimated, but we must prepare ourselves for the implications of this revolution.

The public’s confidence in the pharmacist’s practice and decisions will be a key element for the pharmacist’s place

in the health systems of tomorrow.


48th GIRP Annual General Geeting, 18th June 2007, GENEVA


One must develop the quality and care of pharmacy, but what is the significance of these words if the evolution is not integrated in a

move towards Managed Care?

The demands for continued reform of professional education are accepted but in which direction?

We all know that it should be “patient orientated”but with what conviction and legislation should it be changed?




Patients and consumers are demanding as a right, an internationally high level of safe access to medicines using the logistics of

health care chains.

That means complex stakes concerning medications and their quality, the creation of new work processes and the introduction and

integration of important reforms into health systems.

Other professions want to become involved and have their voice heard, but they are driven and pulled by different

global visions and interests.




The remuneration of the pharmacist must change; this is on the agenda of every professional association.

It is moved by an enormous challenge linked to the professional role of the pharmacist in future

health care systems.

Would you not agree that you have a great responsibility to take up this challenge considering your decision to

become a pharmacy owner?




The integration of the whole concept of patient safety intothe supply chain

The constant reform and development of the way pharmacistsand pharmaceutical scientists are educated

The introduction of services and new professional attitudescentred on the needs of the patients with the objective to reduce health costs.

Assuring the integrity and quality of medicines so that no counterfeit and/or spurious medicines enter into the supply chain




To jointly obtain these common objectives you can bring to us your political and economic influence and your professional contacts

and networking, particularly with the pharmaceutical industry.

In this context we are ready to give you, as independent pharmacists securing the final stage of the chain,

our wheels of innovation, notably the implementation of managed care with our medical colleagues and nurses.




121.7

130.6

139.0143.4

161.8

115.2

126.7130.0

132.6

140.6

100.0

110.0

120.0

130.0

140.0

150.0

160.0

170.0

1999 2000 2001 2002 2003 2004

Evolu

tion d

es c

oûts

en m

édic

am

ents

(In

dic

e)

Contrôle

Cercles qualité "Pionniers" FR

+15.2%

+10.0%

+2.6%+21.7%

+7.3%

+6.4%

+3.2%

+2.0%

+12.8%

+6.0%

Evolution (indice) des coûts médicaments LS par patient des cercles „Pionniers“ fribourgeois

Source de données brutes : OFAC (2005)




2198

1840

2048

2230

2477

23002376

3295

2996

2724 2891

27512650

1000

1200

1400

1600

1800

2000

2200

2400

2600

2800

3000

3200

3400

1998 1999 2000 2001 2002 2003 2004

Année

Coû

t m

édic

amen

ts a

nn

uel

moy

en

par

rés

iden

t [C

HF

]

Comptes AFIPA

Projections AFIPA

Santésuisse: pool de données mai 2005

+ 11.3%

+ 8.9%

+ 11.1%

- 4.1%- 3.2%

+ 10%

+ 10%

+ 3.8%

+ 10%

+ 5.1%

- 4.4%

Locca JF, Bugnon O. Etude comparative 2003-2004 des résultats de l’assistance pharmaceutique appliquée dans les EMS fribourgeois. Nov. 2005




NSAIDS- prescription COXIBS 2003-2004

21.2

10.8

14.0

22.2

8.8

12.7

0.0

5.0

10.0

15.0

20.0

25.0

Contrôle Romandie PIONNIERS FR NOUVEAUX FR

Pourc

enta

ge d

'em

ballages C

OX

IBE

S

2003 2004

Source de données brutes : OFAC (2005)




As conclusion, FIP wishes to share with you clearly identifiable objectives:

The integration of the whole concept of patient safety into the supply chain

The constant reform of pharmaceutical education and professional development

The introduction of patient-centred services and new professional attitudes,

based on the real needs of the patients with the objective to reduce health costs.

expectations for the provision of medicines dr michel buchmann fip vice president 48th girp annual...

Documents

fip vicepresidentone

fip vicepresidentpatients

fip vicepresidentcase

care of pharmacy

health costs

managed care

health systems of tomorrow

medical centre